Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer.
Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Burrello T, Abu-Khalaf M, Sabbath K, Sanft T, Brandt DS, Hofstatter EW, Hatzis C, DiGiovanna MP, Pusztai L. Foldi J, et al. Breast Cancer Res Treat. 2018 Jun;169(2):333-340. doi: 10.1007/s10549-017-4653-2. Epub 2018 Feb 2. Breast Cancer Res Treat. 2018. PMID: 29396664 Clinical Trial.
Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade.
Casadevall D, Li X, Powles RL, Wali VB, Buza N, Pelekanou V, Dhawan A, Foldi J, Szekely B, Lopez-Giraldez F, Hatzis C, Pusztai L. Casadevall D, et al. Among authors: foldi j. JCO Precis Oncol. 2019 May 10;3:PO.18.00335. doi: 10.1200/PO.18.00335. eCollection 2019. JCO Precis Oncol. 2019. PMID: 32914041 Free PMC article. No abstract available.
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer.
Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Foldi J, et al. NPJ Breast Cancer. 2021 Feb 8;7(1):9. doi: 10.1038/s41523-021-00219-7. NPJ Breast Cancer. 2021. PMID: 33558513 Free PMC article.
Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer.
Foldi J, Silber A, Reisenbichler E, Singh K, Fischbach N, Persico J, Adelson K, Katoch A, Horowitz N, Lannin D, Chagpar A, Park T, Marczyk M, Frederick C, Burrello T, Ibrahim E, Qing T, Bai Y, Blenman K, Rimm DL, Pusztai L. Foldi J, et al. NPJ Breast Cancer. 2022 Feb 3;8(1):17. doi: 10.1038/s41523-022-00392-3. NPJ Breast Cancer. 2022. PMID: 35115541 Free PMC article. No abstract available.
Comprehensive Analysis of Metabolic Isozyme Targets in Cancer.
Marczyk M, Gunasekharan V, Casadevall D, Qing T, Foldi J, Sehgal R, Shan NL, Blenman KRM, O'Meara TA, Umlauf S, Surovtseva YV, Muthusamy V, Rinehart J, Perry RJ, Kibbey R, Hatzis C, Pusztai L. Marczyk M, et al. Among authors: foldi j. Cancer Res. 2022 May 3;82(9):1698-1711. doi: 10.1158/0008-5472.CAN-21-3983. Cancer Res. 2022. PMID: 35247885 Free PMC article.
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.
Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Blenman KRM, et al. Among authors: foldi j. Clin Cancer Res. 2022 Jun 13;28(12):2587-2597. doi: 10.1158/1078-0432.CCR-21-3215. Clin Cancer Res. 2022. PMID: 35377948 Free PMC article. Clinical Trial.
Cancer Relevance of Human Genes.
Qing T, Mohsen H, Cannataro VL, Marczyk M, Rozenblit M, Foldi J, Murray M, Townsend JP, Kluger Y, Gerstein M, Pusztai L. Qing T, et al. Among authors: foldi j. J Natl Cancer Inst. 2022 Jul 11;114(7):988-995. doi: 10.1093/jnci/djac068. J Natl Cancer Inst. 2022. PMID: 35417011 Free PMC article.
112 results